**Information for authors**

**Revista Brasileira de Hematologia e Hemoterapia**

Brazilian Journal of Hematology and Hemothherapy

The *Revista Brasileira de Hematologia e Hemoterapia*, ISSN 1516 8484, the official scientific publication of the Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular, Sociedade Brasileira de Transplante de Medula Óssea, Associação Italo-Brasileira di Ematologia and Sociedade Brasileira de Oncologia Pediátrica aims to promote scientific development in Hematology, Transfusion Medicine and related areas. All manuscripts, after initial acceptance by the editors, will be sent for analysis by two peer reviewers. Anonymity is guaranteed throughout the evaluation process. When considered necessary, a list of modifications will be sent to authors to correct their work or justify their decision not to do so.

The responsibility for opinions expressed in articles is solely of the authors.

Manuscripts should not be submitted simultaneously to more than one journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Reproduction, in full or in part, translated into other languages requires prior permission of the editors.

The journal publishes the following sessions: Original Article, Special Article, Review Article, Updates in the Specialty, Case report, Letter to the Editor, Images in Clinical Hematology, Editorial, Scientific Comment and What is the Evidence. Other types of publications of interest in the area will be published at the discretion of the editors. All manuscripts must be submitted in English.

**PREPARATION OF THE MANUSCRIPT**

**GENERAL INFORMATION**

For any manuscript to be evaluated, it must be accompanied by the following documentation:

- **Conflict of interest:** Situations that may improperly influence the development or the conclusions of the work such as participation in drug- or equipment-producing companies cited or used in the work, as well as competitors of these companies should be mentioned. Financial assistance, payments received for consultations, relationships related to employment, etc. are also considered sources of conflict.

- **Approval of the study by a Research Ethics Committee recognized by the National Research Ethics Committee (CONEP);**

- **Articles that deal with clinical research involving human beings must include a statement in the Methods Section that all study participants signed an informed consent form. Authors should also confirm that the study was conducted in accordance with the Helsinki Declaration as revised in 2008;**

- **Experimental studies involving animals should be conducted according to the Ethical Principles for Animal Experimentation recommended by the National Council for the Control of Animal Experimentation (CONCEA, http://www.mct.gov.br/index.php/content/view/363950/0/), Brazilian Law No. 11.794/2008, or equivalent international guidelines. Authors should obtain previous approval from their local Institutional Committee for Ethics in Animal Experimentation or equivalent ethics committee. A statement of protocol approval from an Animal Ethics Committee (CEUA) or equivalent as well as permit numbers must be included in the Methods section of the paper.**

All randomized controlled trials and clinical trials submitted for publication must be registered in a clinical trials database. This is a guideline of the International Clinical Trial Registry Platform (ICTPR) of the World Health Organization (WHO) and the International Committee of Medical Journal Editors (ICMJE). The instructions for the registry are available at: http://www.icmje.org/clinicaltrial.htm and registration can be attained in the Clinical Trials Database of the National Library of Medicine available at: http://clinicaltrials.gov/ct/gui.

**TECHNICAL REQUIREMENTS**

1. **Article identification:** a) A concise however informative title; b) Complete names of authors without abbreviations and their institutions; c) Department and official name of the institution(s) to which the work should be attributed; d) Name, full address including telephone and e-mail of corresponding author; e) financial support (if any).

2. **Abstract and keywords:** Abstract in English of not more than 250 words. For Original Articles this should be structured with background, method, main results and conclusion. For the other article types, the abstract need not be structured but should contain information illustrating the importance of the work. Specify up to five keywords, which define the theme of the paper. The keywords should be based on MeSH (Medical Subject Headings) from the National Library of Medicine available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Mesh. For clinical trials, indicate the International Clinical Trials Registry Number below the summary. Non-standard or uncommon abbreviations should be avoided in the title, abstract, and keywords, but if essential they must be defined at their first mention in the abstract itself.

3. **Manuscript content:** a) **Original Article:** Used to publish the results of scientific research, it must be original and should comprise the following: Introduction, Objective, Method, Results, Discussion, Conclusion and References. The work should not exceed 4000 words (including references), up to 6 authors, up to 7 tables, illustrations and photos and up to 30 references; b) **Special Article:** With the same structure as original articles, Original Articles are reclassified by the Editor depending on their importance. Q) **Review Articles:** narrative reviews addressing an important issue in the specialty. These articles should not exceed 5000 words (including references),
a maximum of 7 tables, Figures and Photos and up to 60 references; d) Update in the Specialty: on a theme, method, treatment, etc. It must contain a brief history of the topic, its current state of knowledge and the reasons for the work, study methods (data sources, selection criteria), hypotheses, study lines, etc., criteria similar to review articles: e) Case Report: should have an introduction with a brief literature review, a description of the case showing significant results for the diagnosis and differential diagnoses (if any), discussion or comments and references. Case reports are not published with abstracts or keywords. It should not exceed 1800 words, two tables, illustrations and photographs, up to four authors and ten references: f) Letters to the Editor: a maximum of 1000 words (including references), three authors, and two illustrations: g) Images in Clinical Hematology: Maximum 100 words, two images, three authors and three references: h) Scientific comments: will only be accepted by invitation of the editors.

4. Acknowledgements: Should be addressed to collaborators who deserve recognition, but whose participation does not justify their inclusion as an author such as technical assistants, as well as financial support received.

5. References: should always be numbered in the order they appear in the text. The format must be based on the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” guidelines proposed by the International Committee of Medical Journal Editors and updated in 2009, as follows: the titles of journals should be abbreviated following the List of Medical Journal Editors and updated in 2009, as follows: the titles of journals should be abbreviated following the List of Journals Indexed in Index Medicus of the National Library of Medicine (http://www.ncbi.nlm.nih.gov/sites/entrez). Cite the first six authors after which add the words et al.

Examples of references: Printed documents


Electronic documents


• Illustrations and photos: Must have a resolution of at least 1000 dpi. Color figures should be in CMYK and will be published in color only if essential and must be in TIFF, JPEG or CDR format. Do not send the figures within the text.

• Tables: should be numbered consecutively using Arabic numerals and cited in the text in numerical order. If the table requires special symbols, it should be sent as a high resolution image (1000 dpi) in TIFF or JPG format.

Submission

The submission of the manuscript must be via the website of the Revista Brasileira de Hematologia e Hemoterapia, (Journal of Hematology and Hemotherapy) www.rbhh.org. Templates of copyright transfer, conflict of interest and animal rights forms are available on the site of the RBHH. All must be completed and uploaded to the submission site. Possible conflicts of interest of any author should be stated.

It is the responsibility of authors to obtain written permission to reproduce any previously published data included in the manuscript.

The editors can publish papers that do not exactly follow the instructions after careful evaluation always taking into account the interests of the readership.

Correspondence address:
Fernando Ferreira Costa
Editor in Chief
Rua Carlos Chagas, 480
Campinas, SP, Brazil
CEP: 13083-970